- 1 Rates of Positive M-CHAT-R Screenings by Pandemic Birth and Prenatal SARS-CoV-2
- 2 **Exposure**
- \*Morgan R. Firestein, Ph.D.<sup>1</sup>, \*Angela Gigliotti Manessis, M.S.<sup>2</sup>, Jen Warmingham, PhD.<sup>3</sup>, 3 Yunzhe Hu, B.A.<sup>1</sup>, Morgan A. Finkel, M.D., M.S.<sup>3,4</sup>, Margaret Kyle, B.A.<sup>3</sup>, Maha Hussain, 4 M.S.<sup>3</sup>, Imaal Ahmed, B.A.<sup>3</sup>, Andréane Lavallée, Ph.D.<sup>3</sup>, Ana Solis<sup>3</sup>, Vitoria Chaves, M.S.<sup>3</sup>, 5 Cynthia Rodriguez, B.A.<sup>3</sup>, Sylvie Goldman, Ph.D.<sup>4,5</sup>, Rebecca A. Muhle, M.D., Ph.D.<sup>1,4,5</sup>, 6 Seonjoo Lee, Ph.D.<sup>1,5,6</sup>, Judy Austin, Ph.D.<sup>7</sup>, Wendy G. Silver, M.D., M.A.<sup>4,8</sup>, Kally C. 7 **O'Reilly**, Ph.D.<sup>1,5</sup>, **Jennifer M. Bain**, M.D., Ph.D.<sup>4,8</sup>, **Anna A. Penn**, M.D., Ph.D.<sup>3,4</sup>, **Jeremy** 8 Veenstra-VanderWeele, M.D., <sup>1,3,4,5</sup>, Melissa S. Stockwell, M.D., M.P.H<sup>3,4,7</sup>, William P. Fifer, Ph.D.<sup>1,3</sup>, Rachel Marsh, Ph.D.<sup>1,8</sup>, Catherine Monk, Ph.D.<sup>1,5,9</sup>, Lauren C. Shuffrey, Ph.D.<sup>10</sup>, 9 10 Dani Dumitriu, M.D., Ph.D.<sup>1,3,4</sup> 11 12 \*Dr. Firestein and Ms. Gigliotti Manessis contributed equally to this article 13 <sup>1</sup>Department of Psychiatry, Columbia University Irving Medical Center, New York, NY 10032 <sup>2</sup>Teachers College, Columbia University, New York, NY 10027 14 <sup>3</sup>Department of Pediatrics, Columbia University Irving Medical Center, New York, NY 10032 15 <sup>4</sup>NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY 10032 16 <sup>5</sup>New York State Psychiatric Institute, New York, NY 10032 17 <sup>6</sup>Department of Biostatistics, Mailman School of Public Health, Columbia University Irving 18 19 Medical Center, New York, NY 10032 <sup>7</sup>Heilbrunn Department of Population and Family Health, Columbia University Irving Medical 20 21 Center, New York, NY 10032 <sup>8</sup>Department of Neurology, Division of Child Neurology, Columbia University Irving Medical 22 23 Center, New York, NY 10032 <sup>9</sup>Department of Obstetrics and Gynecology, Columbia University Irving Medical Center New 24 25 York, NY 10032 <sup>10</sup>Department of Psychiatry, New York University Grossman School of Medicine, New York, 26 27 NY 10016 28
- 29 Corresponding Author:
- 30 Dani Dumitriu, M.D., Ph.D.
- 31 New York State Psychiatric Institute
- 32 Columbia University Irving Medical Center
- 33 1051 Riverside Drive, Suite 4807
- 34 New York, NY 10032
- 35 dani.dumitriu@columbia.edu
- 36
- 37
- 38
- 39
- 40 Abstract

41 Maternal stress and viral illness during pregnancy are associated with neurodevelopmental

- 42 conditions in offspring. Children born during the COVID-19 pandemic, including those exposed
- 43 prenatally to maternal SARS-CoV-2 infections, are reaching the developmental age for the
- 44 assessment of risk for neurodevelopmental conditions. We examined associations between birth
- 45 during the COVID-19 pandemic, prenatal exposure to maternal SARS-CoV-2 infection, and
- 46 rates of positive screenings on the Modified Checklist for Autism in Toddlers-Revised (M-
- 47 CHAT-R). Data were drawn from the COVID-19 Mother Baby Outcomes (COMBO) Initiative.
- Participants completed the M-CHAT-R as part of routine clinical care (COMBO-EHR cohort) or
   for research purposes (COMBO-RSCH cohort). Maternal SARS-CoV-2 status during pregnancy
- was determined through electronic health records. The COMBO-EHR cohort includes n=1664
- 51 children (n=442 historical cohort, n=1222 pandemic cohort; n=997 SARS-CoV-2 unexposed
- 52 prenatally, n=130 SARS-CoV-2 exposed prenatally) who were born at affiliated hospitals
- between 2018-2023 and who had a valid M-CHAT-R score in their health record. The COMBO-
- 54 RSCH cohort consists of n=359 children (n=268 SARS-CoV-2 unexposed prenatally, n=91
- 55 SARS-CoV-2 exposed prenatally) born at the same hospitals who enrolled into a prospective
- cohort study that included administration of the M-CHAT-R at 18-months. Birth during the
- 57 pandemic was not associated with greater likelihood of a positive M-CHAT-R screen in the
- 58 COMBO-EHR cohort. Maternal SARS-CoV-2 was associated with lower likelihood of a positive
- 59 M-CHAT-R screening in adjusted models in the COMBO-EHR cohort (OR=0.40, 95% CI=0.22
- -0.68, p=0.001), while analyses in the COMBO-RSCH cohort yielded similar but non-
- 61 significant results (OR=0.67, 95% CI=0.31-1.37, p=0.29). These results suggest that children
- born during the first 18 months of the COVID-19 pandemic and those exposed prenatally to a
- 63 maternal SARS-CoV-2 infection are not at greater risk for screening positive on the M-CHAT-R.
- 64

65

66

# 68 Introduction

69	Since the onset of the COVID-19 pandemic, we have gained substantial knowledge about
70	the SARS-CoV-2 virus and resulting COVID-19 pathophysiology. However, longitudinal
71	research is needed to determine long-term consequences of early exposure to both the virus and
72	the pandemic environment, especially those affecting the youngest generations. <sup>1–3</sup> Most reports
73	have provided reassuring results suggesting no association between prenatal exposure to
74	maternal SARS-CoV-2 infection and child neurodevelopment. <sup>4–8</sup> One research group found that
75	a higher proportion of prenatally exposed male infants received ICD-10 codes for speech
76	disorders at age 12 months, but not at 18 months. This finding, coupled with a lower-than-
77	expected rate of SARS-CoV-2 infections, suggests a high rate of misclassification and false
78	negatives which may limit the interpretability of these results. <sup>9,10</sup> Further, studies of infants born
79	during previous pandemics have shown that neurodevelopmental needs are frequently
80	unobserved until years later, <sup>11</sup> necessitating additional follow-up.
81	Beyond prenatal exposure to SARS-CoV-2, the COVID-19 generation-the generation
82	born during this pandemic-experienced an unusual environment during infancy and early
83	childhood secondary to societal changes and restrictions. Several reports from diverse
84	populations revealed neurodevelopmental differences between pandemic-born compared to pre-
85	pandemic-born children. <sup>4,6,7,12</sup>
86	The COVID-19 pandemic therefore presents a two-pronged mechanism through which
87	the COVID-19 generation may be at greater risk for neurodevelopmental conditions such as
88	autism spectrum disorders. <sup>6,13</sup> Maternal prenatal psychological distress has been implicated in
89	increased neurodevelopmental risk through a fetal programming framework. <sup>14,15</sup> Separately,
90	maternal immune activation (MIA) is among the potential mechanisms through which prenatal

91 exposure to SARS-CoV-2 has been hypothesized to impact offspring neurodevelopment. 92 Previous outbreaks of human coronaviruses (such as SARS and Middle East Respiratory Syndrome) indicate that severe infection during pregnancy may negatively affect both maternal 93 health and infant well-being, possibly through MIA.<sup>13,16</sup> Based on these premises, we 94 hypothesized that infants exposed to a maternal SARS-CoV-2 in utero would be at increased risk 95 96 of screening positive on the M-CHAT-R. Given the benefits of early intervention,<sup>17,18</sup> special attention should be directed towards 97 evaluating the relationship between fetal exposure to maternal SARS-CoV-2 infection, the 98 99 COVID-19 pandemic environment, and child neurodevelopment. Children who were *in utero* during peak periods of the pandemic are reaching the age at which early indicators of risk for 100 autism may emerge. We compared scores on the parent-report Modified Checklist for Autism in 101 102 Toddlers-Revised (M-CHAT-R) screener between children born before and during the pandemic 103 and those with and without prenatal SARS-CoV-2 exposure. Data were collected as part of the 104 COVID-19 Mother Baby Outcomes (COMBO) Initiative and include clinical M-CHAT-R scores 105 recorded in electronic health records (EHR) and M-CHAT-R scores obtained for research purposes from children born at a large university-based medical center in New York City 106 between January 2018 and September 2021. 107

108

109 Methods

110 Study Design and Participants

Data were drawn from the COVID-19 Mother Baby Outcomes (COMBO) Initiative,
which includes children born at Columbia University Irving Medical Center (CUIMC)-affiliated
NewYork-Presbyterian (NYP) Morgan Stanley Children's Hospital and NYP Allen Pavilion

114	Hospital in New York City between January 2018 and September 2021. COMBO includes an
115	electronic health record (EHR) arm (COMBO-EHR cohort) with a waiver of consent and a
116	prospective research arm (COMBO-RSCH cohort) with on-going enrollment and consent of
117	mother-infant dyads (eFigure 1). Across the two cohorts, demographic and clinical variables,
118	including maternal SARS-CoV-2 status during pregnancy, were acquired through a combination
119	of automated abstraction and manual review of the participants' EHRs. As part of routine clinical
120	care, all CUIMC/NYP-affiliated pediatric clinics began universally administering the M-CHAT-
121	R between 16-30 months of age in February 2020, and scores are recorded in the EHR.
122	Separately, mothers enrolled in COMBO-RSCH are asked to complete the M-CHAT-R at the 18-
123	month study follow-up for research purposes. All study procedures have been reviewed and
124	approved by the CUIMC Institutional Review Board. This study followed the Strengthening the
125	Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines.

126

#### 127 COMBO-EHR Cohort

We identified n=1747 children born in the NYP hospital system during the study period with clinical M-CHAT-R scores in the EHRs. For children with more than one M-CHAT-R score, we used the most recent score obtained within the valid age range. We excluded n=80 children because their only M-CHAT-R score was obtained outside the range of 16-30 months. We excluded an additional n=3 children who received a total M-CHAT-R score of 17 that resulted from all items being marked as "yes," suggesting invalid parental report. In total, we included n=1664 children in COMBO-EHR analyses.

# 136 COMBO-RSCH Cohort

137	At the time of this analysis, the COMBO Initiative had enrolled n=907 mother-infant
138	dyads who had been admitted to the labor & delivery unit and/or well-baby/NICU units of the
139	CUIMC-NYP hospital system in New York City during the study period. Overall, n=421
140	enrolled mothers completed the M-CHAT-R for research purposes as part of a REDCap survey
141	administered at the 18-month study time point. Sixty-two children were excluded from COMBO-
142	RSCH analyses because they had M-CHAT-R scores obtained for both clinical and research
143	purposes. These cases were only included in COMBO-EHR dataset to prioritize the analysis of
144	clinical screening data. In total, we included n=359 children in COMBO-RSCH analyses.
145	
146	Timing of Birth Relative to the COVID-19 Pandemic
147	The COMBO-EHR cohort includes n=442 infants born prior to the COVID-19 pandemic
148	(historical cohort) with dates of birth between January 2018–February 2020 and n=1222 infants
148 149	(historical cohort) with dates of birth between January 2018–February 2020 and n=1222 infants born during the COVID-19 pandemic (pandemic cohort) with dates of birth between March
148 149 150	<ul> <li>(historical cohort) with dates of birth between January 2018–February 2020 and n=1222 infants</li> <li>born during the COVID-19 pandemic (pandemic cohort) with dates of birth between March</li> <li>2020–September 2021. In contrast, all infants in the COMBO-RSCH cohort were born during</li> </ul>
148 149 150 151	<ul> <li>(historical cohort) with dates of birth between January 2018–February 2020 and n=1222 infants</li> <li>born during the COVID-19 pandemic (pandemic cohort) with dates of birth between March</li> <li>2020–September 2021. In contrast, all infants in the COMBO-RSCH cohort were born during</li> <li>the COVID-19 pandemic. Therefore, the historical versus pandemic birth comparison could only</li> </ul>
148 149 150 151 152	<ul> <li>(historical cohort) with dates of birth between January 2018–February 2020 and n=1222 infants</li> <li>born during the COVID-19 pandemic (pandemic cohort) with dates of birth between March</li> <li>2020–September 2021. In contrast, all infants in the COMBO-RSCH cohort were born during</li> <li>the COVID-19 pandemic. Therefore, the historical versus pandemic birth comparison could only</li> <li>be conducted on the COMBO-EHR cohort. Of note, all infants in the COMBO-EHR cohort,</li> </ul>
148 149 150 151 152 153	<ul> <li>(historical cohort) with dates of birth between January 2018–February 2020 and n=1222 infants</li> <li>born during the COVID-19 pandemic (pandemic cohort) with dates of birth between March</li> <li>2020–September 2021. In contrast, all infants in the COMBO-RSCH cohort were born during</li> <li>the COVID-19 pandemic. Therefore, the historical versus pandemic birth comparison could only</li> <li>be conducted on the COMBO-EHR cohort. Of note, all infants in the COMBO-EHR cohort,</li> <li>including those born prior to the pandemic (historical cohort), were assessed <i>during</i> the</li> </ul>
148 149 150 151 152 153 154	<ul> <li>(historical cohort) with dates of birth between January 2018–February 2020 and n=1222 infants</li> <li>born during the COVID-19 pandemic (pandemic cohort) with dates of birth between March</li> <li>2020–September 2021. In contrast, all infants in the COMBO-RSCH cohort were born during</li> <li>the COVID-19 pandemic. Therefore, the historical versus pandemic birth comparison could only</li> <li>be conducted on the COMBO-EHR cohort. Of note, all infants in the COMBO-EHR cohort,</li> <li>including those born prior to the pandemic (historical cohort), were assessed <i>during</i> the</li> <li>pandemic as universal M-CHAT-R screening at pediatric clinics coincided with the onset of the</li> </ul>
148 149 150 151 152 153 154 155	<ul> <li>(historical cohort) with dates of birth between January 2018–February 2020 and n=1222 infants</li> <li>born during the COVID-19 pandemic (pandemic cohort) with dates of birth between March</li> <li>2020–September 2021. In contrast, all infants in the COMBO-RSCH cohort were born during</li> <li>the COVID-19 pandemic. Therefore, the historical versus pandemic birth comparison could only</li> <li>be conducted on the COMBO-EHR cohort. Of note, all infants in the COMBO-EHR cohort,</li> <li>including those born prior to the pandemic (historical cohort), were assessed <i>during</i> the</li> <li>pandemic as universal M-CHAT-R screening at pediatric clinics coincided with the onset of the</li> <li>pandemic for unrelated reasons. Thus, every child in the COMBO-EHR cohort had <i>postnatal</i></li> </ul>
148 149 150 151 152 153 154 155 156	<ul> <li>(historical cohort) with dates of birth between January 2018–February 2020 and n=1222 infants</li> <li>born during the COVID-19 pandemic (pandemic cohort) with dates of birth between March</li> <li>2020–September 2021. In contrast, all infants in the COMBO-RSCH cohort were born during</li> <li>the COVID-19 pandemic. Therefore, the historical versus pandemic birth comparison could only</li> <li>be conducted on the COMBO-EHR cohort. Of note, all infants in the COMBO-EHR cohort,</li> <li>including those born prior to the pandemic (historical cohort), were assessed <i>during</i> the</li> <li>pandemic as universal M-CHAT-R screening at pediatric clinics coincided with the onset of the</li> <li>pandemic for unrelated reasons. Thus, every child in the COMBO-EHR cohort had <i>postnatal</i></li> <li>exposure to the pandemic environment.</li> </ul>

# 158 Determination of Prenatal Maternal SARS-CoV-2 Infection

159	Maternal SARS-CoV-2 status during pregnancy was determined through EHR
160	abstraction and review. Detailed descriptions of our methods for determining maternal SARS-
161	CoV-2 status during pregnancy have been reported previously <sup>4,5</sup> and are outlined in eFigure 2.
162	Briefly, on March 22, 2020, CUIMC began universal testing of all delivering patients for SARS-
163	CoV-2 through nasopharyngeal polymerase chain reaction (PCR) and on July 20, 2020, universal
164	serology testing for SARS-CoV-2 antibodies was implemented. Infants born before November 1,
165	2020, were considered exposed during pregnancy if their mother had a positive PCR and/or
166	serological test during pregnancy or at delivery. If their mother had a negative PCR test and no
167	available serological test result, they were classified as unexposed. For infants born after
168	November 1, 2020, mothers could have had a pre-pregnancy infection that would result in a
169	positive serology test during pregnancy. Therefore, these infants were considered exposed during
170	pregnancy if their mother had a positive PCR and/or antigen test during pregnancy. If their
171	mothers did not have a recorded positive PCR or antigen test but had a positive serological test
172	and COVID-19 symptoms during the pregnancy, they were also considered exposed. Infants
173	were classified as unexposed if their mother had a positive serology test during pregnancy or at
174	the time of delivery, but had no symptoms during the pregnancy, had negative serological
175	testing, or had no serology test results and no symptoms during the pregnancy determined
176	through manual chart review. We have previously estimated that this approach has a 0.67%
177	false-negative rate (eMethods 1).

178

# 179 Modified Checklist for Autism in Toddlers (M-CHAT-R)

180	The M-CHAT-R was developed to assess risk for autism based on parent report of their
181	child's development between 16-30 months of age and consists of twenty 'yes'/'no' items that
182	focus on a child's milestones as well as early autism symptoms that present between the normed
183	age span. <sup>19</sup> Total scores are calculated and categorized into ranges of "low-risk" (0-2); "medium-
184	risk" (3-7); "high-risk" (8-20). To improve power, we collapsed across the medium-risk and
185	high-risk ranges to define a medium/high-risk range, which we defined as screening positive.
186	The M-CHAT-R has been validated as having high sensitivity and specificity as a measure for
187	likelihood of autism, with diagnoses confirmed through a variety of measures such as the Autism
188	Diagnostic Observation Schedule and is widely adopted by clinicians. <sup>20,21</sup> The M-CHAT-R was
189	administered in either English or Spanish depending on the caregiver's preference.

190

#### 191 Statistical analysis

192 Statistical analyses were conducted in R version 4.3.1 (R Foundation for Statistical Computing).<sup>22</sup> M-CHAT-R scores were obtained through EHR review for the COMBO-EHR 193 cohort and using a forced-choice online survey for the COMBO-RSCH cohort, resulting in no 194 missingness of data. Since participants in both cohorts were born in the same hospital system, all 195 196 demographic variables and other covariates were obtained via the EHRs. For each of our three 197 primary analyses, we performed separate unadjusted Chi-squared tests and multivariable logistic regression models. Using data from the COMBO-EHR cohort, we performed an unadjusted Chi-198 199 squared test and an adjusted logistic regression model to assess the association between birth 200 during the COVID-19 pandemic and a positive screening on the M-CHAT-R. For the subset of COMBO-EHR children born during the COVID-19 pandemic and the COMBO-RSCH cohort, 201 202 we performed an unadjusted Chi-squared test and a multivariable logistic regression model to

203 determine the association between prenatal maternal SARS-CoV-2 status and positive screening 204 on the M-CHAT-R. All multivariable models included as covariates the child's age at 205 assessment, sex assigned at birth, maternal race and ethnicity, mode of delivery, gestational age 206 at delivery, maternal age at delivery, and insurance type as a proxy for socioeconomic status (Medicaid versus commercial). To examine potential demographic differences between groups, 207 208 comparisons were performed using Chi-squared tests for binomial variables and Wilcoxon rank 209 sum tests for continuous variables. For the primary analyses, we report Chi-squared results for 210 univariate models and odds ratios (ORs) with 95% confidence intervals (CIs) for multivariable 211 models. For all analyses, we conducted separate subgroup analyses of full-term and preterm 212 children, as well as subgroup analyses of male and female children. For analyses of SARS-CoV-2 exposure within both COMBO-EHR and COMBO-RSCH cohorts, we conducted an additional 213 214 sensitivity analysis omitting cases without serology testing in the EHR. Finally, we compared the 215 proportion of children screening positive on the M-CHAT-R and the age at assessment across the 216 COMBO-RSCH and COMBO-EHR cohorts using independent samples t-tests and Chi-squared 217 tests. All sensitivity analyses used multivariable models. Significance was set at p<0.05. 218

219 Results

## 220 Cohort Characteristics

The COMBO-EHR cohort included n=1664 children, n=442 born before March 2020 (historical cohort) and n=1222 born during the COVID-19 pandemic. In the pandemic-born group, 95 dyads lacked maternal PCR and serology data or had unknown infection timing, resulting in n=997 and n=130 SARS-CoV-2 unexposed and exposed children, respectively. Characteristics of the mother-child dyads included in the COMBO-EHR cohort are summarized

in Table 1. The mean maternal age at delivery was  $30 \pm 6.24$  years. The pandemic cohort 226 differed significantly from the historical cohort in maternal age at delivery (p=0.002), self-227 reported race ( $\chi^2$ =597.91, df=6, p<0.001), ethnicity ( $\chi^2$ =596.41, df=3, p<0.001), infant 228 gestational age (p=0.02), child's age at M-CHAT-R assessment (p<0.01), and infant sex at birth 229  $(\gamma^2=6.97, df=1, p=0.008)$  (Table 1). Mothers in the SARS-CoV-2 exposed cohort differed 230 significantly from the unexposed cohort in their self-reported race ( $\gamma^2$ =8.63, df=5, p=0.12) and 231 ethnicity ( $\chi^2$ =12.31, df=2, p=0.002) (Table 1). Group differences were accounted for in all fully 232 233 adjusted models. 234 The COMBO-RSCH cohort (n=359) demographic characteristics are summarized in 235 Table 2. The mean maternal age at delivery was  $32 \pm 5.08$  years. Mother-child dyads with (n=91) and without (n=268) SARS-CoV-2 exposure during pregnancy were compared on the same 236 237 sociodemographic characteristics described above. Mothers with a history of SARS-CoV-2 infection during pregnancy differed significantly from unexposed mothers in their self-reported 238 ethnicity ( $\gamma^2$ =9.16, df=3, p=0.03). Additionally, exposed children were significantly younger at 239 240 the time of the M-CHAT-R assessment (p=0.03). Group differences were accounted for in all 241 fully adjusted models. Additional analyses comparing the COMBO-EHR and COMBO-RSCH cohorts are 242 described in eMethods 2. 243

244

### 245 Birth During the Pandemic and M-CHAT-R Positive Screening: COMBO-EHR Cohort

There was no difference in the proportion of children screening positive on the M-CHAT-R between the historical and pandemic cohorts ( $\chi^2$ =0.03, *df*=1, *p*=0.87). Specifically,

248	22% (n=100) of the children in the historical cohort and 23% (n=283) of the children in the
249	pandemic cohort screened positive (Figure 1A). The lack of an association between birth during
250	the pandemic and M-CHAT-R positivity was maintained in a fully adjusted model accounting
251	for maternal age, child age at assessment, child sex, race, ethnicity, gestational age, and
252	insurance (OR=0.75, 95% CI=0.52–1.08, p=0.12) (Table 3). Similar non-significant findings
253	were observed in adjusted subgroup analyses of preterm (n=204) and full-term subsamples
254	(n=1460) (eTable 1) and in adjusted subgroup analyses of male (n=880) and female (n=784)
255	children (eTable 2).

256

# 257 Prenatal Maternal SARS-CoV-2 Infection and M-CHAT-R Positive Screenings: COMBO 258 EHR Cohort

There was a significant association between SARS-CoV-2 exposure during pregnancy 259 260 and less likelihood of M-CHAT-R positive screenings, which was in the opposite direction as hypothesized ( $\gamma^2$ =8.28, df=1, p=0.004). Specifically, 23% (n=239) of unexposed children and 261 262 12% (n=16) of exposed children screened positive on the M-CHAT-R (Figure 1B). This association remained significant in a fully adjusted model (OR=0.40, 95% CI=0.22-0.68, 263 264 p=0.004) (Table 4) and persisted in sensitivity analyses excluding cases with elevated potential for misclassification of SARS-CoV-2 exposure due to missing serology testing (n=427, 265 266 OR=0.43, 95% CI=0.22–0.81, p=0.01) (eTable 3). Among full-term children, a lower proportion 267 of children with SARS-CoV-2 exposure screened positive on the M-CHAT-R (n=982, adjusted 268 OR=0.45, 95% CI=0.24–0.79, p=0.01), whereas this association did not reach statistical 269 significance among preterm children (n=145, OR=0.16, 95% CI=0.01–0.84, p=0.07) (eTable 4).

Within both female and male subsamples, a lower proportion of children with SARS-CoV-2
exposure screened positive on the M-CHAT-R (females: n=555, adjusted OR=0.30 95%
CI=0.10-0.71, p=0.01; males: n=572, OR=0.48, 95% CI=0.23-0.93, p=0.04) (eTable 5).
Prenatal Maternal SARS-CoV-2 Infection and M-CHAT-R Positive Screenings: COMBO-
RSCH Cohort
Overall, fewer SARS-CoV-2 exposed children screened positive (13%, n=12) compared
to 17% (n=47) of unexposed children in the COMBO-RSCH cohort (Figure 1C). However, this
association was not statistically significant ( $\chi^2=0.65$ , $df=1$ , $p=0.42$ ). The lack of a significant
association persisted in a fully adjusted model with the same covariates as those used in the
COMBO-EHR analysis (OR=0.67, 95% CI=0.31–1.37, <i>p</i> =0.25) (Table 4). Similar non-
significant associations were observed in adjusted subgroup analyses of preterm (n=37) and full-
term subsamples (n=322) (eTable 6) and in subgroup analyses of male (n=199) and female
(n=160) children (eTable 7).
Discussion
Considering the conflicting evidence on the relationship between COVID-19 and infant
neurodevelopment, continued long-term monitoring of the COVID-19 generation is important
for public health and educational policy. We evaluated the neurodevelopmental risk of children
born before and during the COVID-19 pandemic and those with and without prenatal SARS-
CoV-2 exposure using the M-CHAT-R in a demographically diverse sample in New York City.

291 We found that children born before versus during the pandemic did not have significantly

different M-CHAT-R positivity rates. Contrary to our hypothesis, we found that maternal SARSCoV-2 infection during pregnancy was not associated with increased risk for a positive autism
screen based on the M-CHAT-R.

Overall, our sample had higher M-CHAT-R positivity rates compared to other samples (22-23% compared to 9% in a general population).<sup>23</sup> Participants in our analysis primarily reside in an urban city, where the prevalence of autism diagnoses is higher, potentially due to increased access to healthcare services or environmental exposures unique to urban areas.<sup>24</sup> Our cohort has a uniquely high percentage of Hispanic participants, a population found to have higher positivity rates on the M-CHAT-R.<sup>25–27</sup> Further, validity on the Spanish version of the M-CHAT-R was conducted in Spain, which is culturally different from our study sample.<sup>28</sup>

In our sample, maternal SARS-CoV-2 exposure during pregnancy was not associated 302 with increased risk for screening positive on the M-CHAT-R. Research suggests that SARS-303 CoV-2 may cause MIA, with moderate but temporary changes in cytokine levels in pregnant 304 women<sup>29</sup> that could be associated with infant neurodevelopmental risk.<sup>10</sup> Our findings align with 305 306 other reports of no or limited associations between prenatal SARS-CoV-2 exposure and infant neurodevelopment.<sup>4,5,7,12</sup> Many of these studies, however, including ours, primarily include 307 308 participants with mild illness. Additional exploration of the relationship between severity of 309 infection and neurodevelopment is needed.

Of note, the percentage of children who were exposed to SARS-CoV-2 in utero had positivity rates that were closer to the expected rate in a general population; whereas the unexposed children had a higher-than-expected M-CHAT-R positivity rate.<sup>30</sup> It is possible that unmeasured differences between the exposed and unexposed cohorts in conjunction with the subjective nature of the M-CHAT-R could contribute to the unexpected direction of this

315 association. Data suggest that maternal dispositional variables relate to reporting of their child's 316 behavior.<sup>31</sup> Mothers who experienced greater stress and vigilance towards the prevention of SARS-CoV-2 may be less likely to become infected and more likely to monitor and report 317 concerning behaviors through the M-CHAT-R.<sup>32,33</sup> Additionally, the unexpected positivity rates 318 may be due to limitations of the M-CHAT-R as a research tool. We used only one M-CHAT-R 319 score, without follow-up, for each participant. Finally, it is important to note that all children 320 321 were assessed during the pandemic and had some amount of postnatal exposure to the pandemic 322 environment. Therefore, our analyses are limited to *prenatal* associations and cannot evaluate 323 associations between *postnatal* experiences and M-CHAT-R positivity. Our findings suggest that neither SARS-CoV-2 infection nor birth during the pandemic is 324 associated with increased risk for autism. For many, the social and economic impact of the 325 326 pandemic will persist in the years to come and may continue to impact the developmental trajectories of the COVID-19 generation.<sup>34</sup> There may also be intergenerational consequences 327 that could worsen existing inequalities.<sup>35</sup> Furthermore, data suggest that the impact of prenatal 328 exposures may not manifest until higher cognitive functions begin to emerge and mature.<sup>36</sup> The 329 COVID-19 pandemic has resulted in increased mental health needs amongst pregnant and 330 postpartum individuals,<sup>37</sup> and higher levels of the stress hormone cortisol during pregnancy is 331 associated with lower offspring educational attainment.<sup>38</sup> At the same time, the pandemic 332 catalyzed a number of changes in the education system.<sup>39</sup> Continued monitoring of this 333 generation is important to develop targeted and appropriate policies in education and welfare. 334 335 336

l by the
Pediatrics,
Center,
e COVID-19
ish to thank
collaborative
bia University
ılar gratitude
our
ursement for
ing: design
ne data;
uscript for
onsibility for
ingham,

# 360 **References**

361	1.	López-Díaz, Á., Ayesa-Arriola, R., Crespo-Facorro, B. & Ruiz-Veguilla, M. COVID-19
362		Infection During Pregnancy and Risk of Neurodevelopmental Disorders in Offspring: Time
363		for Collaborative Research. Biol. Psychiatry 89, e29-e30 (2021).
364	2.	Ahmed, W. N., Noushin, A. M., Shafjeer, A. & Ann, R. COVID-19 and Pregnancy: Time to
365		Think beyond Medications. 11.
366	3.	Martins-Filho, P. R., Tanajura, D. M., Santos, H. P. & Santos, V. S. COVID-19 during
367		pregnancy: Potential risk for neurodevelopmental disorders in neonates? Eur. J. Obstet.
368		Gynecol. Reprod. Biol. 250, 255–256 (2020).
369	4.	Shuffrey, L. C. et al. Association of Birth During the COVID-19 Pandemic With
370		Neurodevelopmental Status at 6 Months in Infants With and Without In Utero Exposure to
371		Maternal SARS-CoV-2 Infection. JAMA Pediatr. e215563 (2022)
372		doi:10.1001/jamapediatrics.2021.5563.
373	5.	Firestein, M. R. et al. Assessment of Neurodevelopment in Infants With and Without
374		Exposure to Asymptomatic or Mild Maternal SARS-CoV-2 Infection During Pregnancy.
375		JAMA Netw. Open 6, e237396 (2023).
376	6.	Brum, A. C. & Vain, N. E. Impact of perinatal COVID on fetal and neonatal brain and
377		neurodevelopmental outcomes. Semin. Fetal. Neonatal Med. 28, 101427 (2023).
378	7.	Ayed, M. et al. Neurodevelopmental outcomes of infants born to mothers with SARS-CoV-2
379		infections during pregnancy: a national prospective study in Kuwait. BMC Pediatr. 22, 319
380		(2022).
381	8.	Pinheiro, G. S. M. A. et al. Effects of intrauterine exposure to SARS-CoV-2 on infants'
382		development: a rapid review and meta-analysis. Eur. J. Pediatr. 182, 2041–2055 (2023).

383	9.	Edlow.	A.G.	. Castro.	V. M.	Shook.	. L. L.	. Kaimal	A. J.	& Perlis.	R. H.
	· ·			,	,	, ~	,	,			

384 Neurodevelopmental Outcomes at 1 Year in Infants of Mothers Who Tested Positive for

385 SARS-CoV-2 During Pregnancy. JAMA Netw. Open 5, e2215787 (2022).

- 10. Edlow, A. G. *et al.* Sex-Specific Neurodevelopmental Outcomes Among Offspring of
- 387 Mothers With SARS-CoV-2 Infection During Pregnancy. *JAMA Netw. Open* **6**, e234415
- 388 (2023).
- 11. Almond, D. Is the 1918 Influenza Pandemic Over? Long Term Effects of In Utero
- 390 Influenza Exposure in the Post□1940 U.S. Population. J. Polit. Econ. **114**, 672–712 (2006).
- 12. Hessami, K. et al. COVID-19 Pandemic and Infant Neurodevelopmental Impairment: A
- 392 Systematic Review and Meta-analysis. *JAMA Netw. Open* **5**, e2238941 (2022).
- 393 13. San Martín-González, N. *et al.* Maternal respiratory viral infections during pregnancy and
  394 offspring's neurodevelopmental outcomes: A systematic review. *Neurosci. Biobehav. Rev.*395 149, 105178 (2023).
- 14. van den Bergh, B. R. H., Dahnke, R. & Mennes, M. Prenatal stress and the developing brain:
  Risks for neurodevelopmental disorders. *Dev. Psychopathol.* 30, 743–762 (2018).
- 398 15. Manzari, N., Matvienko-Sikar, K., Baldoni, F., O'Keeffe, G. W. & Khashan, A. S. Prenatal
- 399 maternal stress and risk of neurodevelopmental disorders in the offspring: a systematic
- 400 review and meta-analysis. *Soc. Psychiatry Psychiatr. Epidemiol.* **54**, 1299–1309 (2019).
- 401 16. Diriba, K., Awulachew, E. & Getu, E. The effect of coronavirus infection (SARS-CoV-2,
- 402 MERS-CoV, and SARS-CoV) during pregnancy and the possibility of vertical maternal-
- 403 fetal transmission: a systematic review and meta-analysis. *Eur. J. Med. Res.* 25, 39 (2020).
- 404 17. Fernell, E., Eriksson, M. A. & Gillberg, C. Early diagnosis of autism and impact on
- 405 prognosis: a narrative review. *Clin. Epidemiol.* **5**, 33–43 (2013).

406	18.	Gran	eesheh.	D.,	Dixon.	D. 1	R.,	Tarbox.	J.,	. Kar	olan.	A. 1	M. 8	ک Wilke	. A.	E.	The effects	of a	ige
				,	, , ,		7			,					,				· — —

407 and treatment intensity on behavioral intervention outcomes for children with autism

408 spectrum disorders. *Res. Autism Spectr. Disord.* **3**, 1014–1022 (2009).

- 19. Robins, D. L., Barton, M. & Fein, D. Modified Checklist for Autism in Toddlers, Revised
- 410 with Follow-up. American Psychological Association https://doi.org/10.1037/t67574-000
- 411 (2018).
- 412 20. Aishworiya, R., Ma, V. K., Stewart, S., Hagerman, R. & Feldman, H. M. Meta-analysis of

the Modified Checklist for Autism in Toddlers, Revised/Follow-up for Screening. *Pediatrics* 

- 414 **151**, e2022059393 (2023).
- 415 21. Wieckowski, A. T., Williams, L. N., Rando, J., Lyall, K. & Robins, D. L. Sensitivity and
- 416 Specificity of the Modified Checklist for Autism in Toddlers (Original and Revised): A

417 Systematic Review and Meta-analysis. *JAMA Pediatr.* **177**, 373–383 (2023).

- 418 22. R Core Team. R: A language and environment for statistical computing. R Foundation for
  419 Statistical Computing (2021).
- 420 23. Chlebowski, C., Robins, D. L., Barton, M. L. & Fein, D. Large-Scale Use of the Modified
- 421 Checklist for Autism in Low-Risk Toddlers. *Pediatrics* **131**, e1121–e1127 (2013).
- 422 24. Lauritsen, M. B. *et al.* Urbanicity and Autism Spectrum Disorders. *J. Autism Dev. Disord.*423 44, 394–404 (2014).
- 424 25. Kimple, K. S., Bartelt, E. A., Wysocki, K. L. & Steiner, M. J. Performance of the Modified
- 425 Checklist for Autism in Toddlers in Spanish-Speaking Patients. *Clin. Pediatr. (Phila.)* 53,
- 426 632–638 (2014).

- 427 26. Rea, K. E., Armstrong-Brine, M., Ramirez, L. & Stancin, T. Ethnic Disparities in Autism
- 428 Spectrum Disorder Screening and Referral: Implications for Pediatric Practice. J. Dev.
- 429 *Behav. Pediatr. JDBP* **40**, 493–500 (2019).
- 430 27. Windham, G. C., Lyall, K., Anderson, M. & Kharrazi, M. Autism Spectrum Disorder Risk in
- 431 Relation to Maternal Mid-Pregnancy Serum Hormone and Protein Markers from Prenatal
- 432 Screening in California. J. Autism Dev. Disord. 46, 478–488 (2016).
- 433 28. Magán-Maganto, M. *et al.* Spanish Cultural Validation of the Modified Checklist for Autism
  434 in Toddlers, Revised. *J. Autism Dev. Disord.* 50, 2412–2423 (2020).
- 435 29. Jain, S., Allen, I. E., Song, D. & Piao, X. Cytokine responses to SARS-COV2 infection in
- 436 mother-infant dyads: a systematic review and meta-analysis. *Front. Pediatr.* 11, 1277697
  437 (2023).
- 30. Robins, D. L. *et al.* Validation of the Modified Checklist for Autism in Toddlers, Revised
  With Follow-up (M-CHAT-R/F). *Pediatrics* 133, 37–45 (2014).
- 440 31. Durbin, C. E. & Wilson, S. Convergent validity of and bias in maternal reports of child
- 441 emotion. *Psychol. Assess.* **24**, 647–660 (2012).
- 442 32. Crowell, J. A., Keluskar, J. & Gorecki, A. Parenting behavior and the development of
  443 children with autism spectrum disorder. *Compr. Psychiatry* 90, 21–29 (2019).
- 444 33. Gray, P. H., Edwards, D. M., O'Callaghan, M. J. & Gibbons, K. Screening for autism
- spectrum disorder in very preterm infants during early childhood. *Early Hum. Dev.* 91, 271–
  276 (2015).
- 447 34. Benner, A. D. & Mistry, R. S. Child Development During the COVID-19 Pandemic Through
- 448 a Life Course Theory Lens. *Child Dev. Perspect.* **14**, 236–243 (2020).

- 449 35. Fitzgerald, E., Hor, K. & Drake, A. J. Maternal influences on fetal brain development: The
- 450 role of nutrition, infection and stress, and the potential for intergenerational consequences.
- 451 *Early Hum. Dev.* **150**, 105190 (2020).
- 452 36. Konijnenberg, C. Methodological Issues in Assessing the Impact of Prenatal Drug Exposure.
- 453 Subst. Abuse Res. Treat. **9s2**, SART.S23544 (2015).
- 454 37. Firestein, M. R., Dumitriu, D., Marsh, R. & Monk, C. Maternal Mental Health and Infant
- 455 Development During the COVID-19 Pandemic. *JAMA Psychiatry* **79**, 1040–1045 (2022).
- 456 38. Aizer, A., Stroud, L. & Buka, S. Maternal Stress and Child Outcomes: Evidence from
- 457 Siblings. J. Hum. Resour. **51**, 523–555 (2016).
- 458 39. White, M. A. & McCallum, F. Wellbeing and Resilience Education: COVID-19 and Its
- 459 *Impact on Education*. (Routledge, 2021).
- 460
- 461
- 462

# 464 **Figure Captions**

465

- 466 Figure 1. Percent of Children Screening Positive on the M-CHAT-R in the COMBO-EHR and COMBO-RSCH Datasets.
- 467 Dashed grey lines indicate previously reported rates of positivity in low-risk, US samples.

I able 1. Electronic Medical Record (COM	ивО-ЕНК) Cohort	Characteristics		Histor	ical Cohort vs. Iemic Cohort			SAR Unex	S-CoV-2 posed vs.
<b>Variable</b> No. (%) or Median (Min, Max)	Overall Sample (N=1664)	Historical Cohort (N=442)	Pandemic Cohort (n=1222)	p <sup>†</sup>	Test statistic <sup>†</sup>	SARS-CoV-2 Unexposed (N=997)	SARS-CoV-2 Exposed (N=130)	Ех	rposed Test statistic <sup>†</sup>
Maternal Characteristics		<u> </u>	· · ·				· · ·		
Age at Delivery (years)	30 (16, 56)	31.00 (16, 56)	30.00 (17, 55)	0.002	296990	30.00 (17.00, 55.00)	28.00 (17.00, 43.00)	0.08	70947
Insurance				<.001	49.83			0.52	0.42
Commercial	419 (25.18%)	167 (37.78%)	252 (20.62%)			213 (21.36%)	24 (18.46%)		
Medicaid	1245 (74.82%)	275 (62.21%)	970 (79.38%)			784 (78.64%)	106 (81.54%)		
Race				<.001	597.91			0.12	8.63
Black or African American	266 (16%)	71 (16.06%)	195 (15.96%)			166 (16.65%)	18 (13.85%)		
Native American or Alaskan Native	8 (0.48%)	2 (0.45%)	6 (0.49%)			3 (0.30%)	1 (0.77%)		
Asian or Asian American	65 (3.9%)	30 (6.79%)	35 (2.86%)			33 (3.31%)	2 (1.54%)		
White	400 (24.04%)	156 (35.29%)	244 (19.97%)			200 (20.06%)	21 (16.15%)		
Other or Mixed Race	608 (36.54%)	30 (6.79%)	578 (47.30%)			460 (46.14%)	76 (58.46%)		
Declined	180 (10.82%)	16 (3.62%)	164 (13.42%)			135 (13.54%)	12 (9.23%)		
Unknown	137 (8.23%)	137 (31.00%)	0 (0%)			0 (0.00%)	0 (0.00%)		
Ethnicity				<.001	596.41			0.002	12.31
Hispanic or Latino/a/x or Spanish	991 (59.56%)	144 (32.58%)	847 (69.31%)			669 (67.10%)	105 (80.77%)		
Not Hispanic or Latino/a/x or Spanish	398 (23.92%)	114 (25.79%)	284 (23.24%)			247 (24.77%)	23 (17.69%)		
Declined	95 (5.71%)	4 (0.90%)	91 (7.45%)			81 (8.12%)	2 (1.54%)		
Unknown	180 (10.82%)	180 (40.72%)	0 (0%)			0 (0.00%)	0 (0.00%)		
Infant Characteristics									
Age at M-CHAT (months)	23 (16, 30)	24 (16, 30)	21 (16, 30)	<.001	383443	21.42 (16.03, 30.00)	23.36 (16.13, 28.65)	0.04	57762
Gestational Age at Birth (weeks)	39 (23.00, 41.57)	39 (23.00, 41.29)	39.14 (23.86, 41.57)	0.02	249410	39.14 (24.14, 41.57)	39.00 (24.71, 41.29)	0.35	68099
Female Sex	784 (47.12%)	184 (41.62%)	600 (49.10%)	0.01	6.97	490 (49.15%)	65 (50.00%)	0.93	0.01

<sup>†</sup>Comparisons performed using Chi Squared Test for categorical variables and Wilcoxon Rank-Sum test (*W*, rank total) for continuous variables. All statistical tests were two-sided.

Table 2. COMBO Research (COMBO-RSCH) Cohort Characteristic
--

Variable No. (%) or Median (Min, Max)			SARS-CoV-2 Exposed (N=91)	SARS-CoV-2 Unexposed vs. Exposed	
	Overall Sample (N=359)	SARS-CoV-2 Unexposed (N=268)		p <sup>†</sup>	Test statistic <sup>†</sup>
Maternal Characteristics					
Age at Delivery (years)	32 (5)	32 (5)	32 (5)	0.70	12524
Insurance				0.84	0.35
Commercial	216 (60.2%)	163 (69.8%)	55 (60.4%)		
Medicaid	143 (39.8%)	105 (39.2%)	36 (39.6%)		
Race				0.21	8.34
Black or African American	36 (10%)	30 (11.2%)	6 (6.6%)		
Native American or Alaskan Native	3 (0.8%)	2 (0.7%)	2 (2.2%)		
Native Hawaiian or Other Pacific Islander	1 (0.3%)	1 (0.4%)	0 (0%)		
Asian or Asian American	12 (3.3%)	10 (3.7%)	2 (2.2%)		
White	153 (42.6%)	120 (44.8%)	32 (35.2%)		
Other or Mixed Race	96 (26.7%)	63 (23.5%)	33 (36.3%)		
Declined or Unknown	60 (16.7%)	42 (15.7%)	17 (18.7%)		
Ethnicity				0.03	9.16
Hispanic or Latino/a/x or Spanish	151 (42.1%)	103 (38.4%)	48 (52.7%)		
Not Hispanic or Latino/a/x or Spanish	157 (43.7%)	126 (47.0%)	31 (34.1%)		
Declined or Unknown	51 (14.2%)	39 (14.6%)	12 (13.2%)		
Infant Characteristics					
Age at M-CHAT (months)	18.44 (1.07) (16.53, 27)	18.23 (1.21) (16.53, 23.9)	18.04 (0.89) (16.53, 27)	<0.001	184167
Gestational Age at Birth (weeks)	38.77 (1.74) (30.57, 41.57)	39.14 (1.72) (30.57, 41.43)	39.00 (1.81) (30.57, 41.57)	0.90	12222

Female Sex	160 (44.6%)	115 (42.9%)	45 (49.5%)	0.34	0.93
------------	-------------	-------------	------------	------	------

Table 3. Comparison of Rates of Positive M-CHAT Screenings Between the Historical (n=442) and Pandemic (n=1222) Cohorts (COMBO-EH $^{4/3}$					
Predictor	В	SE	Odds Ratio	95% CI	P-value <sup>474</sup>
Pandemic Birth (Reference: Born on or after 03/01/2020)	-0.29	0.19	0.75	0.52 - 1.08	0.12 475
Age at M-CHAT administration (months)	-0.04	0.02	0.96	0.93 - 1.00	0.05 476
Gestational age (weeks)	-0.10	0.03	0.90	0.86 - 0.95	<.001477
Maternal age at delivery >35	-0.01	0.01	0.99	0.97 -1.01	0.16 478
Infant sex assigned at birth (Male)	0.61	0.12	1.84	1.45 - 3.12	<.001 <sub>479</sub>
Insurance (Medicaid)	0.75	0.20	2.11	1.45 - 3.14	<.001
Maternal Race-American Indian or Alaska Native	-0.30	1.12	0.74	0.04 - 4.72	0.78
Maternal Race-Asian	0.08	0.44	1.08	0.43 - 2.45	0.86 481
Maternal Race–Black or African American	0.34	0.20	1.41	0.95 - 2.09	0.10 482
Maternal Race-Declined	0.29	0.23	1.33	0.83 - 2.10	<sup>0.22</sup> 483
Maternal Race–Other Combinations Not Described	0.26	0.31	1.29	0.71 - 2.35	0.41
Maternal Race–White	0.09	0.18	1.10	0.77 - 1.56	0.61 484
Maternal Ethnicity-Not Hispanic or Latino or Spanish Origin	-0.29	0.19	0.75	0.51 - 1.09	0.13 485

Table 4. Comparison of Rates of Positive M-CHAT Screenings Between SARS-CoV-2 Exposed and Unexposed Infants Across the COMBO-EHR and COMBO-RSCH Cohorts						
Predictor	В	SE	Odds Ratio	95% CI	P-value	
COMBO-EHR Cohort						
SARS-CoV-2 Infection in pregnancy (n=130 exposed; n=997 unexposed)	-0.91	.28	0.40	0.22 - 0.68	0.004	
Age at M-CHAT administration (months)	-0.04	0.02	0.96	0.92 - 1.01	0.09	
Gestational age (weeks)	-0.13	0.04	0.88	0.82 - 0.93	<.001	

Maternal age at delivery	-0.01	0.01	0.99	0.96 - 1.01	0.34
Infant sex assigned at birth (Male)	0.54	0.15	1.71	1.28 - 2.30	<.001
Insurance (Medicaid)	0.56	0.25	1.75	1.09 - 2.87	0.02
Maternal Race-American Indian or Alaska Native	0.37	1.27	1.45	0.064 - 14.64	0.77
Maternal Race-Asian	-0.13	0.59	0.88	0.24 - 2.58	0.83
Maternal Race-Black or African American	0.26	0.24	1.29	0.80 - 2.08	0.29
Maternal Race-Declined	0.46	0.26	1.58	0.95 - 2.60	0.07
Maternal Race–White	-0.05	-0.06	0.95	0.61 - 1.45	0.80
Maternal Ethnicity–Declined	-0.55	0.36	0.58	0.28 - 1.14	0.12
Maternal Ethnicity–Not Hispanic or Latino or Spanish Origin	-0.39	0.24	0.68	0.42 - 1.08	0.11
COMBO-RSCH Cohort					
SARS-CoV-2 Infection in pregnancy (n=91 exposed; n=268 unexposed)	-0.42	0.37	0.67	0.31 - 1.37	0.25
Age at M-CHAT administration (months)	-0.30	0.13	0.75	0.56-0.98	0.03
Gestational age (weeks)	-0.26	0.09	0.75	0.56 - 0.98	0.005
Maternal age at delivery	-0.10	0.03	0.91	0.85-0.98	0.004
Infant sex assigned at birth (Male)	0.78	0.34	2.18	1.15-4.30	0.02
Insurance (Medicaid)	0.30	0.40	1.35	6.18-2.98	0.45
Maternal Race-American Indian or Alaska Native	0.93	1.40	2.53	0.10-35.94	0.51
Maternal Race-Asian	1.11	0.82	3.03	0.54- 14.18	0.18
Maternal Race-Black or African American	0.12	0.56	1.13	0.36-3.32	0.83
Maternal Race-Declined	-0.81	0.63	0.45	0.12-1.43	0.19
Maternal Race–White	-0.12	0.44	0.89	0.37-2.09	0.79
Maternal Ethnicity–Declined	0.18	0.59	1.20	0.36-3.81	0.76
Maternal Ethnicity–Not Hispanic or Latino or Spanish Origin	-0.56	0.46	0.57	0.23-1.39	0.22



